{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T01:29:09Z","timestamp":1794878949110,"version":"4.9.1"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T00:00:00Z","timestamp":1730678400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016259","name":"Viatris Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016259","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005614","name":"Biogen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020957","name":"Roche Germany Holding GmbH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022606","name":"Almirall SA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022606","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014756","name":"Hexal AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014756","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008792","name":"Novartis Pharma GmbH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Europe"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.lanepe.2024.101137","type":"journal-article","created":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T18:40:15Z","timestamp":1733164815000},"page":"101137","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Impact of disease-modifying therapies on pregnancy outcomes in multiple sclerosis: a prospective cohort study from the German multiple sclerosis and pregnancy registry"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-9762-1315","authenticated-orcid":false,"given":"Nadine","family":"Bast","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Dost-Kovalsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Haben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Friedmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Witt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Oganowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Thiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Hellwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.lanepe.2024.101137_bib1","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S1474-4422(22)00426-4","article-title":"Family planning considerations in people with multiple sclerosis","volume":"22","author":"Krysko","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.lanepe.2024.101137_bib2","series-title":"Guideline on risk assessment of medicinal products on human reproduction and lactation: from data to labelling","year":"2008"},{"issue":"9","key":"10.1016\/j.lanepe.2024.101137_bib3","first-page":"2721","article-title":"A\u00a0systematic review and meta-analyses of pregnancy and fetal outcomes in women with multiple sclerosis: a contribution from the IMI2 ConcePTION project","volume":"267","author":"Lopez-Leon","year":"2020","journal-title":"J\u00a0Neurol"},{"issue":"1","key":"10.1016\/j.lanepe.2024.101137_bib4","doi-asserted-by":"crossref","first-page":"e1114","DOI":"10.1212\/NXI.0000000000001114","article-title":"Interim analysis of pregnancy outcomes after exposure to dimethyl fumarate in a prospective international registry","volume":"9","author":"Hellwig","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.lanepe.2024.101137_bib5","series-title":"Updated restrictions for Gilenya: multiple sclerosis medicine not to be used in pregnancy","author":"EMA","year":"2019"},{"issue":"7","key":"10.1016\/j.lanepe.2024.101137_bib6","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1177\/1352458519843055","article-title":"Pregnancy outcomes in patients with multiple sclerosis treated with teriflunomide: clinical study data and 5 years of post-marketing experience","volume":"26","author":"Vukusic","year":"2020","journal-title":"Mult Scler"},{"issue":"7","key":"10.1016\/j.lanepe.2024.101137_bib7","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s40264-020-00948-x","article-title":"Pregnancy outcomes during the clinical development program of cladribine in multiple sclerosis: an integrated analysis of safety","volume":"43","author":"Giovannoni","year":"2020","journal-title":"Drug Saf"},{"key":"10.1016\/j.lanepe.2024.101137_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102146","article-title":"Pregnancy outcomes and postpartum relapse rates in women with RRMS treated with alemtuzumab in the phase 2 and 3 clinical development program over 16 years","volume":"43","author":"Oh","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"3","key":"10.1016\/j.lanepe.2024.101137_bib9","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.neurol.2020.05.005","article-title":"Pregnancy with multiple sclerosis","volume":"177","author":"Vukusic","year":"2021","journal-title":"Rev Neurol"},{"key":"10.1016\/j.lanepe.2024.101137_bib10","series-title":"Tysabri: EPAR - product information. June 06, 2024","year":"2009"},{"issue":"1","key":"10.1016\/j.lanepe.2024.101137_bib11","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000913","article-title":"Anti-CD20 therapies and pregnancy in neuroimmunologic disorders: a cohort study from Germany","volume":"8","author":"K\u00fcmpfel","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.lanepe.2024.101137_bib12","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211054956","article-title":"The German multiple sclerosis and pregnancy registry: rationale, objective, design, and first results","volume":"14","author":"Thiel","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.lanepe.2024.101137_bib13","series-title":"Common terminology criteria for adverse events (CTCAE). Version 5.0","year":"2017"},{"issue":"5","key":"10.1016\/j.lanepe.2024.101137_bib14","first-page":"210","article-title":"[New percentile values for the anthropometric dimensions of singleton neonates: analysis of perinatal survey data of 2007-2011 from all 16 states of Germany]","volume":"218","author":"Voigt","year":"2014","journal-title":"Z\u00a0Geburtshilfe Neonatol"},{"key":"10.1016\/j.lanepe.2024.101137_bib15","series-title":"EUROCAT guide 1.5 chapter 3.1: overview of EUROCAT approach to coding and classification","year":"2022"},{"key":"10.1016\/j.lanepe.2024.101137_bib16","series-title":"Analyse des Neugeborenenkollektivs der Bundesrepublik Deutschland. 12 Mitteilung: Vorstellung engmaschiger Perzentilwerte (-kurven) f\u00fcr die K\u00f6rperma\u00dfe Neugeborener","first-page":"956","volume":"66","author":"Voigt","year":"2006"},{"key":"10.1016\/j.lanepe.2024.101137_bib17","series-title":"Prevalence charts and tables - updated data including birth year 2022. April, 2024","year":"2022"},{"key":"10.1016\/j.lanepe.2024.101137_bib18","doi-asserted-by":"crossref","DOI":"10.1177\/1756286418804760","article-title":"Evaluation of pregnancy outcomes in patients with multiple sclerosis after fingolimod exposure","volume":"11","author":"Geissb\u00fchler","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"issue":"1","key":"10.1016\/j.lanepe.2024.101137_bib19","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/cpt.2476","article-title":"From inception to ConcePTION: genesis of a network to support better monitoring and communication of medication safety during pregnancy and breastfeeding","volume":"111","author":"Thurin","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.lanepe.2024.101137_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2021.110041","article-title":"Physiological and pathological functions of sphingolipids in pregnancy","volume":"85","author":"Fakhr","year":"2021","journal-title":"Cell Signal"},{"key":"10.1016\/j.lanepe.2024.101137_bib21","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/985646","article-title":"IgG placental transfer in healthy and pathological pregnancies","volume":"2012","author":"Palmeira","year":"2012","journal-title":"Clin Dev Immunol"},{"issue":"4","key":"10.1016\/j.lanepe.2024.101137_bib22","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000734","article-title":"And pregnancy","volume":"7","author":"Smith","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.lanepe.2024.101137_bib23","series-title":"Maternal and infant infection following treatment with rituximab or natalizumab prior to or during pregnancy. ECTRIMS","author":"Gorczyca","year":"2023"},{"key":"10.1016\/j.lanepe.2024.101137_bib24","article-title":"Role of maternal age and pregnancy history in risk of miscarriage: prospective register based study","volume":"364","author":"Magnus","year":"2019","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.lanepe.2024.101137_bib25","doi-asserted-by":"crossref","first-page":"584S","DOI":"10.1093\/ajcn\/85.2.584S","article-title":"Low birth weight in the United States","volume":"85","author":"Goldenberg","year":"2007","journal-title":"Am J Clin Nutr"},{"issue":"5","key":"10.1016\/j.lanepe.2024.101137_bib26","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1177\/1352458508101937","article-title":"Does multiple sclerosis increase risk of adverse pregnancy outcomes? A population-based study","volume":"15","author":"Chen","year":"2009","journal-title":"Mult Scler"},{"key":"10.1016\/j.lanepe.2024.101137_bib27","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1600-0404.2006.00616.x","article-title":"Planned vaginal births in women with multiple sclerosis: delivery and birth outcome","volume":"183","author":"Dahl","year":"2006","journal-title":"Acta Neurol Scand Suppl"},{"issue":"11 Suppl 5","key":"10.1016\/j.lanepe.2024.101137_bib28","first-page":"S12","article-title":"A\u00a0multimodal approach to managing the symptoms of multiple sclerosis","volume":"63","author":"Crayton","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.lanepe.2024.101137_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.873253","article-title":"Infections and pregnancy: effects on maternal and child health","volume":"12","author":"Kumar","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"issue":"5","key":"10.1016\/j.lanepe.2024.101137_bib30","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1001\/jamaneurol.2015.4800","article-title":"Vitamin D status during pregnancy and risk of multiple sclerosis in offspring of women in the Finnish maternity cohort","volume":"73","author":"Munger","year":"2016","journal-title":"JAMA Neurol"},{"issue":"6","key":"10.1016\/j.lanepe.2024.101137_bib31","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.3945\/ajcn.115.123752","article-title":"Maternal vitamin D concentrations during pregnancy, fetal growth patterns, and risks of adverse birth outcomes","volume":"103","author":"Miliku","year":"2016","journal-title":"Am J Clin Nutr"},{"issue":"1","key":"10.1016\/j.lanepe.2024.101137_bib32","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1365-3016.2010.01147.x","article-title":"Does in utero exposure to synthetic glucocorticoids influence birthweight, head circumference and birth length? A systematic review of current evidence in humans","volume":"25","author":"Khan","year":"2011","journal-title":"Paediatr Perinat Epidemiol"},{"issue":"1","key":"10.1016\/j.lanepe.2024.101137_bib33","article-title":"Pregnancy outcome following exposure to ocrelizumab in multiple sclerosis","volume":"8","author":"Chey","year":"2022","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"10.1016\/j.lanepe.2024.101137_bib34","series-title":"Encyclopedia of reproduction","first-page":"370","article-title":"Formation and growth of the fetus","author":"Forhead","year":"2018"},{"key":"10.1016\/j.lanepe.2024.101137_bib35","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1136\/jnnp-2023-332804","article-title":"Disease activity and neonatal outcomes after exposure to natalizumab throughout pregnancy","volume":"95","author":"Thiel","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"10.1016\/j.lanepe.2024.101137_bib36","first-page":"e823","article-title":"Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: fetal risks","volume":"90","author":"Portaccio","year":"2018","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.lanepe.2024.101137_bib37","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.44750","article-title":"Multiple sclerosis disease activity and disability following discontinuation of natalizumab for pregnancy","volume":"5","author":"Hellwig","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.lanepe.2024.101137_bib38","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200110","article-title":"Multiple sclerosis disease activity and disability following cessation of fingolimod for pregnancy","volume":"10","author":"Hellwig","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"10.1016\/j.lanepe.2024.101137_bib39","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.reprotox.2003.10.007","article-title":"Pregnancy outcome after first trimester exposure to corticosteroids: a prospective controlled study","volume":"18","author":"Gur","year":"2004","journal-title":"Reprod Toxicol"},{"issue":"9","key":"10.1016\/j.lanepe.2024.101137_bib40","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1177\/13524585211069068","article-title":"The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: eighth European committee for treatment and research in multiple sclerosis focused workshop review. April 2021","volume":"28","author":"Tur","year":"2022","journal-title":"Mult Scler"},{"issue":"5","key":"10.1016\/j.lanepe.2024.101137_bib41","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/ana.20858","article-title":"Immune surveillance in multiple sclerosis patients treated with natalizumab","volume":"59","author":"St\u00fcve","year":"2006","journal-title":"Ann Neurol"},{"key":"10.1016\/j.lanepe.2024.101137_bib42","series-title":"Krankenhaus-report 2023: schwerpunkt: personal","first-page":"305","article-title":"Auswirkungen der Covid-19-Pandemie im Krankenhaus: Fallzahlentwicklung und Charakteristika der Covid-19-Patienten","author":"Hentschker","year":"2023"},{"issue":"4","key":"10.1016\/j.lanepe.2024.101137_bib43","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200264","article-title":"Neonatal B-cell levels and infant health in newborns potentially exposed to anti-CD20 monoclonal antibodies during pregnancy or lactation","volume":"11","author":"Schwake","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"3","key":"10.1016\/j.lanepe.2024.101137_bib44","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1177\/13524585221131486","article-title":"Cladribine and pregnancy in women with multiple sclerosis: the first cohort study","volume":"29","author":"Dost-Kovalsky","year":"2023","journal-title":"Mult Scler"}],"container-title":["The Lancet Regional Health - Europe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776224003065?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776224003065?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T08:52:28Z","timestamp":1736499148000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666776224003065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":44,"alternative-id":["S2666776224003065"],"URL":"https:\/\/doi.org\/10.1016\/j.lanepe.2024.101137","relation":{},"ISSN":["2666-7762"],"issn-type":[{"value":"2666-7762","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of disease-modifying therapies on pregnancy outcomes in multiple sclerosis: a prospective cohort study from the German multiple sclerosis and pregnancy registry","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Europe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2024.101137","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101137"}}